title: Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
abstract: Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC- and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.
authors.affiliation: a Universitat Autònoma de Barcelona , Barcelona , Spain.|b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.
authors.forename: Concepción
authors.initials: C
authors.lastname: Fernández-Rodríguez
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|c Servei d'Hematologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.affiliation: d Human Anatomy Unit, School of Medicine, Universitat de Barcelona , Barcelona , Spain.
authors.forename: Alfons
authors.initials: A
authors.lastname: Navarro
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|c Servei d'Hematologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Gimeno
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|e Servei de Patologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Silvia
authors.initials: S
authors.lastname: Pairet
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Camacho
authors.affiliation: c Servei d'Hematologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Mariana
authors.initials: M
authors.lastname: Ferraro
authors.affiliation: e Servei de Patologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Sergi
authors.initials: S
authors.lastname: Serrano
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|c Servei d'Hematologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Carles
authors.initials: C
authors.lastname: Besses
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|e Servei de Patologia, Hospital del Mar , Barcelona , Spain.|f Universitat Pompeu Fabra , Barcelona , Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Bellosillo
authors.affiliation: b IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.|c Servei d'Hematologia, Hospital del Mar , Barcelona , Spain.
authors.forename: Blanca
authors.initials: B
authors.lastname: Sanchez-Gonzalez
mesh_terms: D000107:Acetylation; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000069461:Bendamustine Hydrochloride / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics; D053903:DNA Breaks, Double-Stranded / Q000187:drug effects; D015870:Gene Expression; D016158:Genes, p53; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006657:Histones / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics; D000077337:Vorinostat
chemical_list: D000970:Antineoplastic Agents; D050759:Cyclin-Dependent Kinase Inhibitor p21; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; D000077337:Vorinostat; D000069461:Bendamustine Hydrochloride
keywords: Bendamustine; TP53; diffuse large B-cell lymphoma; histone deacetylase inhibitor; vorinostat